192 related articles for article (PubMed ID: 30403784)
21. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Furuta T; Shirai N; Xiao F; El-Omar EM; Rabkin CS; Sugimura H; Ishizaki T; Ohashi K
Clin Gastroenterol Hepatol; 2004 Jan; 2(1):22-30. PubMed ID: 15017629
[TBL] [Abstract][Full Text] [Related]
22. Gastric Juice-Based Real-Time PCR for Tailored
Peng X; Song Z; He L; Lin S; Gong Y; Sun L; Zhao F; Gu Y; You Y; Zhou L; Zhang J
Int J Med Sci; 2017; 14(6):595-601. PubMed ID: 28638276
[TBL] [Abstract][Full Text] [Related]
23. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori.
Lin YA; Wang H; Gu ZJ; Wang WJ; Zeng XY; Du YL; Ying SS; Zhang BH
Med Sci Monit; 2017 Jun; 23():2701-2707. PubMed ID: 28577017
[TBL] [Abstract][Full Text] [Related]
24. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
[TBL] [Abstract][Full Text] [Related]
25. [Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory
Zhang YD; Dong QW; Zhang SH; Gu F; Zhang Y; Song HB; Zuo NY; Zhang SS; Ma L; Ding ZL
Zhonghua Er Ke Za Zhi; 2020 Jan; 58(1):41-45. PubMed ID: 31905475
[No Abstract] [Full Text] [Related]
26. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Kawabata H; Habu Y; Tomioka H; Kutsumi H; Kobayashi M; Oyasu K; Hayakumo T; Mizuno S; Kiyota K; Nakajima M; Kimoto K; Inokuchi H; Kawai K
Aliment Pharmacol Ther; 2003 Jan; 17(2):259-64. PubMed ID: 12534411
[TBL] [Abstract][Full Text] [Related]
27. CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection.
Auttajaroon J; Chotivitayatarakorn P; Yamaoka Y; Vilaichone RK
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1243-1247. PubMed ID: 31030500
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
[TBL] [Abstract][Full Text] [Related]
29. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
30. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
[TBL] [Abstract][Full Text] [Related]
31. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial.
Hong J; Shu X; Liu D; Zhu Y; Xie C; Xie Y; Zhang K; Wang A; Xiong H; Zeng H; Yu H; Ma J; Chen Y; Zhu X; Lu N
J Antimicrob Chemother; 2016 Aug; 71(8):2280-5. PubMed ID: 27107097
[TBL] [Abstract][Full Text] [Related]
32. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy.
Arévalo Galvis A; Trespalacios Rangel AA; Otero Regino W
Helicobacter; 2019 Jun; 24(3):e12574. PubMed ID: 30859680
[TBL] [Abstract][Full Text] [Related]
33. Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia.
Nabinger DD; Mazzoleni LE; Sander GB; Mazzoleni F; Osório MC; Klein MG; Rech TF; Basso da Silva L; de Moraes GS; Cristovam RA; Nardelli EF; Francesconi CF; Simon D
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706745
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
[TBL] [Abstract][Full Text] [Related]
35. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Hokari K; Sugiyama T; Kato M; Saito M; Miyagishima T; Kudo M; Nishikawa K; Ishizuka J; Komatsu Y; Mizushima T; Kagaya H; Hige S; Takeda H; Asaka M
Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
[TBL] [Abstract][Full Text] [Related]
37. Microarray-Based Detection and Clinical Evaluation for
Song Y; Dou F; Zhou Z; Yang N; Zhong J; Pan J; Liu Q; Zhang J; Wang S
Biomed Res Int; 2018; 2018():2684836. PubMed ID: 30276203
[No Abstract] [Full Text] [Related]
38. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
[TBL] [Abstract][Full Text] [Related]
39. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
[TBL] [Abstract][Full Text] [Related]
40. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
